The results from T24 tumor xenograft model also showed that the combination treatment of IFN-α and roflumilast (5 mg/kg/day) potentiated the anti-tumor effect of IFN-α through the cAMP reduction (Additional file 7: Figure S7A-D). This evidence concerns the gene IFNA2 and neoplasm.